Protagonist Therapeutics (PTGX) EPS (Basic) (2017 - 2025)
Historic EPS (Basic) for Protagonist Therapeutics (PTGX) over the last 9 years, with Q3 2025 value amounting to -$0.62.
- Protagonist Therapeutics' EPS (Basic) fell 1481.48% to -$0.62 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.77, marking a year-over-year decrease of 7335.64%. This contributed to the annual value of $4.47 for FY2024, which is 42156.35% up from last year.
- Per Protagonist Therapeutics' latest filing, its EPS (Basic) stood at -$0.62 for Q3 2025, which was down 1481.48% from -$0.55 recorded in Q2 2025.
- Over the past 5 years, Protagonist Therapeutics' EPS (Basic) peaked at $3.41 during Q1 2024, and registered a low of -$0.84 during Q2 2022.
- For the 5-year period, Protagonist Therapeutics' EPS (Basic) averaged around -$0.19, with its median value being -$0.58 (2023).
- In the last 5 years, Protagonist Therapeutics' EPS (Basic) plummeted by 23333.33% in 2021 and then skyrocketed by 60895.52% in 2024.
- Over the past 5 years, Protagonist Therapeutics' EPS (Basic) (Quarter) stood at -$0.77 in 2021, then increased by 9.09% to -$0.7 in 2022, then skyrocketed by 174.29% to $0.52 in 2023, then soared by 311.29% to $2.14 in 2024, then plummeted by 128.99% to -$0.62 in 2025.
- Its last three reported values are -$0.62 in Q3 2025, -$0.55 for Q2 2025, and -$0.19 during Q1 2025.